Liu Y, Lei T, Shi Y, Wang X Y, Sun M L, Fan W X, Zhang Z N, Jiang M
Hematologic Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology , Urumqi, Xinjiang 830054, China.
Zhonghua Yi Xue Za Zhi. 2018 Mar 6;98(9):682-687. doi: 10.3760/cma.j.issn.0376-2491.2018.09.012.
To explore the expression and significance of Set gene in Acute myeloid leukemia (AML) patients , and to analyze its effect for the prognosis of AML. The level of Set gene expression was detected by real-time PCR in 59 AML patients and 20 heathy people. The mutations in C-kit 8/17 gene, NPM1 gene and FLT3-TKD/ITD gene in 59 AML patients were detected by direct sequencing. The level of Set gene expression[1.41(0.41-3.31)]was significantly higher in 59 AML patients.The expression of Set gene was correlated with the percentage of marrow blasts and CR in AML patients (=0.040, <0.001); the CR rate of Set gene high expression group was significantly lower than that of Set gene low expression group(32.1% vs 83.9%, =0.01). In the intermediate-risk of AML patients with chromosome karyotype analysis, the CR rate of Set gene high expression group and low expression group were 34.8% and 88.9%, and there are significantly different between two groups(<0.001); univariate and multivariate analysis showed that Set gene high expression group correlated with poor OS[4(2-15)months]and EFS[3(2-13)months])(=0.021, =0.017). It suggests that the Set gene maybe one of AML independent poor prognostic marker.The level of Set gene expression did not correlate with sex, age, WBC, HGB, PLT, FAB typing, chromosomal karyotype and NPM1, C-Kit8/17, CEBPa, FLT3-ITD/TKD gene mutations in AML patients(all >0.05). The level of Set gene expression in bone marrow maybe play an important role in AML. The high expression of Set gene indicates poor prognosis in AML patients.
探讨Set基因在急性髓系白血病（AML）患者中的表达及意义，并分析其对AML预后的影响。采用实时荧光定量PCR检测59例AML患者及20例健康对照者Set基因的表达水平。采用直接测序法检测59例AML患者C-kit 8/17基因、NPM1基因及FLT3-TKD/ITD基因的突变情况。59例AML患者Set基因表达水平[1.41(0.41 - 3.31)]显著高于健康对照者。Set基因表达与AML患者骨髓原始细胞比例及完全缓解率相关（r = 0.040，P < 0.001）；Set基因高表达组完全缓解率显著低于低表达组（32.1% vs 83.9%，P = 0.01）。在染色体核型分析为中危的AML患者中，Set基因高表达组与低表达组完全缓解率分别为34.8%和88.9%，两组差异有统计学意义（P < 0.001）；单因素及多因素分析显示，Set基因高表达组总生存期[4(2 - 15)个月]及无事件生存期[3(2 - 13)个月]较差（P = 0.021，P = 0.017）。提示Set基因可能是AML独立的不良预后标志物。Set基因表达水平与AML患者的性别、年龄、白细胞计数、血红蛋白、血小板计数、FAB分型、染色体核型及NPM1、C-Kit8/17、CEBPa、FLT3-ITD/TKD基因突变均无相关性（均P > 0.05）。骨髓中Set基因表达水平可能在AML中起重要作用。Set基因高表达提示AML患者预后不良。
